Order Article Reprints

Park YS, Kang SB, Marchelletta RR, Penrose HM, Ruiter-Visser R, Jung B, Docherty MJ, Boland BS, Sandborn WJ, McCole DF. The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients. Pharmaceutics. 2023; 15(3):811. https://doi.org/10.3390/pharmaceutics15030811

Park, Young Su, Sang Bum Kang, Ronald R. Marchelletta, Harrison M. Penrose, Roos Ruiter-Visser, Barbara Jung, Michael J. Docherty, Brigid S. Boland, William J. Sandborn, and Declan F. McCole. 2023. "The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients" Pharmaceutics 15, no. 3: 811. https://doi.org/10.3390/pharmaceutics15030811

Park, Y. S., Kang, S. B., Marchelletta, R. R., Penrose, H. M., Ruiter-Visser, R., Jung, B., Docherty, M. J., Boland, B. S., Sandborn, W. J., & McCole, D. F. (2023). The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients. Pharmaceutics, 15(3), 811. https://doi.org/10.3390/pharmaceutics15030811